Physician profile
Roman I Krivochenitser
NPI 1336553874
$40,574.29
in general payments reported to CMS, 2019-2025
26 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.09 · 2020: $847 · 2021: $602 · 2022: $2,436 · 2023: $8,119 · 2024: $7,701 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $4,012 · Travel and Lodging: $2,136 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,450.00 |
| Food and Beverage | $4,011.88 |
| Travel and Lodging | $2,136.26 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $35,484.31 | 2020-2025 | Hydrus Microstent, Voyager Dslt, Centurion |
| Sight Sciences, INC. | $2,460.02 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $764.46 | 2022-2025 | |
| Allergan, INC. | $615.93 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $167.62 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $135.60 | 2022-2024 | Vyzulta |
| Carl Zeiss Meditec USA, INC. | $111.69 | 2023 | Artevo 800 |
| Nova Eye, INC. | $97.24 | 2025 | |
| Rxsight INC | $93.93 | 2022 | |
| Ivantis, INC | $89.15 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $84.67 | 2021-2023 | Cequa |
| Glaukos Corporation | $77.30 | 2020-2023 | |
| Apellis Pharmaceuticals, INC. | $69.90 | 2022-2023 | |
| Biotissue Holdings INC. | $58.87 | 2023-2024 | |
| Astellas Pharma US INC | $36.75 | 2024 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.96 | 2024 | Eylea |
| Tarsus Pharmaceuticals, INC. | $27.26 | 2024 | Xdemvy |
| Genentech USA, INC. | $26.31 | 2023 | Vabysmo |
| Amgen INC. | $23.62 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $22.36 | 2025 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $20.70 | 2022 | |
| Dompe US, INC. | $19.19 | 2024 | Oxervate |
| Thea Pharma INC. | $19.07 | 2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.12 | 2021 | |
| Ocular Therapeutix, INC. | $14.39 | 2020 | |
| New World Medical,INC. | $8.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Krivochenitser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.